SCHEMBL29958561

SCHEMBL29958561

NC(=O)C1CCc2ccc(Cl)cc2C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 8/20 0.52
MAPT P10636 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
DRD2 P14416 1/20 0.42
DRD3 P35462 1/20 0.42
SIRT2 Q8IXJ6 3/20 0.40
SIRT3 Q9NTG7 2/20 0.40
SRD5A1 P18405 2/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
HDAC8 Q9BY41 2/20 0.39
EPHX2 P34913 1/20 0.39
AHR P35869 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27033341 1.00 SIRT1 (0.52) SIRT1MAPTL3MBTL1DRD2DRD3
SCHEMBL29174303 0.94 SIRT1 (0.48) SIRT1MAPTL3MBTL1DRD2DRD3
SCHEMBL29958290 0.85 NOTUM (0.43) MAPTDRD2DRD3SRD5A1HTR2A
SCHEMBL27033717 0.85 NOTUM (0.43) MAPTDRD2DRD3SRD5A1HTR2A
SCHEMBL367380 0.81 KDM1A (0.46) SIRT1DRD2DRD3HDAC8
SCHEMBL27033455 0.80 MAPT (0.43) MAPTL3MBTL1HDAC8SMN1; SMN2
SCHEMBL29958397 0.80 MAPT (0.43) MAPTL3MBTL1HDAC8SMN1; SMN2
SCHEMBL29174302 0.78 SIRT1 (0.36) SIRT1MAPTL3MBTL1DRD2DRD3
SCHEMBL346421 0.78 PLAU (0.52)
SCHEMBL30711622 0.78 PLAU (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4308228-A1 PLASMA KALLIKREIN INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2024-01-24 EP disclosed
CN-117396474-A Plasma kallikrein inhibitors 武田药品工业株式会社 2024-01-12 CN disclosed
WO-2022197756-A1 PLASMA KALLIKREIN INHIBITORS SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed